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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: Statin-induced inhibition of HMG-CoA reductase reduces cholesterol production and 
prevents the formation of many non-steroidal isoprenoid compounds, such as farnesylpyrophos-
phate and geranylgeranylpyrophosphate, that act as lipid attachments for the post-translational 
modiﬁ  cation of various proteins, including the G-proteins and transcription factors involved in 
a number of cell processes. However, the blockade of isoprenylation elicited by statin treatment 
also has biological effects on cell function that go beyond the decrease in cholesterol synthesis: 
these are the so-called “pleiotropic” effects that mainly relate to vascular function. Endothelial 
dysfunction is an independent predictor of cardiovascular events that correlates with inﬂ  am-
mation markers/mediators and robust predictors of cardiovascular diseases such as increased 
high-sensitivity C-reactive protein levels. The results of in vivo and in vitro studies indicate 
that the statins have beneﬁ  cial effects unrelated to cholesterol lowering, such as improving 
endothelial function, increasing myocardial perfusion, and enhancing the availability of nitric 
oxide. This review describes the pleiotropic effects of statins that may be involved in modulat-
ing/preventing endothelial dysfunction and inﬂ  ammatory processes, as well as the cellular and 
molecular mechanisms through which they improve endothelial function.
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Introduction
The endothelium is a monocellular layer lining the inside of vessels that normally 
provides a non-adhesive, non-thrombogenic surface for blood constituents, and acts 
as a dynamic interface regulating blood vessel functions (Behrendt and Ganz 2002). 
It inﬂ  uences responses to environmental and endogenous factors by generating para-
crine and autocrine mediators that control the biology of the entire vessel wall. The 
endothelium plays a pivotal role in regulating vascular tone, but also controls other 
physiological process such as inﬂ  ammation, coagulation and thrombosis.
Persistent hemodynamic or inﬂ  ammatory factors activate the endothelium and 
lead to it becoming dysfunctional. In particular, endothelial cell activation by cyto-
kines or other inﬂ  ammatory mediators increases the expression of a variety of cell 
surface adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and 
vascular cell adhesion molecule-1 (VCAM-1), procoagulants and anticoagulants, 
and substances regulating vasomotor tone. One hallmark of endothelium dysfunction 
is an altered response to endothelium-dependent and endothelium-independent stimuli, 
such as acetylcholine and bradykinin (Harrison 1997). These effects are due to a 
reduced bioavailability of nitric oxide (NO), which may be caused by a decrease in 
the synthesis, release and/or activity of endothelial-derived NO.
It is now known that abnormal endothelium function can be detected before the 
establishment of obvious intimal lesions in patients with risk factors for atherosclerosis 
(Celermajer et al 1992), and endothelial dysfunction of the coronary or peripheral Vascular Health and Risk Management 2006:2(4) 465–475
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arteries is an independent predictor of cardiovascular events, 
even after adjusting for traditional factors (Ganz and Vita 
2003). Endothelial dysfunction correlates with inﬂ  ammation 
markers/mediators and robust predictors of cardiovascular 
diseases, such as increased high-sensitivity C-reactive pro-
tein (hs-CRP) levels in subjects with coronary artery disease 
(Fichtlscherer et al 2000). This observation is of particular 
interest because CRP stimulates the expression of VCAM-1, 
thus highlighting once again the link between inﬂ  ammation 
and endothelial dysfunction (Pasceri et al 2000). Further-
more, it has been suggested that enhanced endothelial func-
tion may contribute to improved clinical status (Anderson 
et al 1995; Treasure et al 1995).
Experimental and clinical studies have shown that 
hypercholesterolemia, a major risk factor for vascular 
diseases, impairs endothelium function (Creager et al 1990; 
Egashira et al 1993), and LDL apheresis alone rapidly exerts 
beneﬁ  cial effects on endothelial vasodilator function within 
a few hours (Tamai et al 1997).
It has been shown that, in addition to reducing atheroscle-
rosis and cardiovascular events, lipid-lowering therapies and 
particularly 3-hydroxy-3-methylglutaryl coenzyme A (HMG 
CoA) reductase inhibitors (commonly known as statins) 
improve endothelium function, and numerous clinical stud-
ies have demonstrated that this is not necessarily related to 
a detectable decrease in serum cholesterol levels.
The first evidence that statins may inhibit cardio-
vascular events regardless of their effects on blood cho-
lesterol levels came from the WOSCOPS study, which 
found that the incidence of cardiovascular events in a 
subgroup of patients treated with placebo or statin with 
the same LDL-cholesterol level was markedly lower in 
the statin group (WOSCOPS Study Group 1998). The 
beneficial effects of statins may occur relatively soon 
after the start of therapy and are different from those 
observed after the reduction of plasma cholesterol levels 
(Buchwald et al 1995). The cholesterol-independent, 
anti-thrombotic, anti-oxidative and anti-inflamma-
tory vascular effects of statins are known as pleiotropic 
effects (Davignon 2004; Halcox and Deanfield 2004). 
The most important underlying mechanism is mediated 
by a reduction in the synthesis of mevalonate, which is 
not only a precursor of cholesterol, but also of a variety 
of non-steroidal isoprenoid compounds that are essential 
for normal cell activity (Corsini et al 1999; Wolfrum 
et al 2003). Isoprenoids, such as farnesylpyrophosphate 
and geranylpyrophosphate, are essential for the cell 
membrane attachment of important regulatory proteins, 
particularly small GTPase: by inhibiting its synthesis, 
statins deplete cells of these lipids and thus elicit the 
retention of small GTPase in the cytosol, where they 
cannot exert their biological actions.
Statins and endothelial 
NO synthase (eNOS) expression
The initial studies of endothelial function concentrated on 
vasomotion, which became the major parameter of endothe-
lial health. Endothelium-dependent vasodilatation primarily 
occurs via the release of a humoral mediator (identiﬁ  ed as 
NO), rather than prostacyclin and an endothelium-derived 
hyperpolarisation factor (Kansui et al 2004).
Well documented data from experimental and clinical 
studies show that statins increase eNOS expression and 
activation, which may be the principal mechanism by which 
statins improve endothelial dysfunction in addition to reduce 
cholesterol levels. Interestingly, statins can modulate NO 
bioavailability by increasing mRNA expression or increas-
ing eNOS activity: the ﬁ  rst is a late effect and involves 
inhibiting the isoprenylation of Rho, small GTPase proteins, 
whereas the second is much more rapid and requires a lower 
statin concentration. It must also be remembered that statins 
maintain NO availability by preventing its degradation by 
free radical molecules (Koh 2000).
NO bioavailability is mediated 
by Rho inhibition
Rho proteins are small GTPases that regulate cytoskeleton 
organization and cell adhesion, thus contributing to cell mi-
gration and endothelial permeability (Nobes and Hall 1999; 
Ridley 1995). Their function is strictly regulated by their 
membrane localization, which is favored by prenylation, 
a post-translational modiﬁ  cation that helps anchor them to 
membranes.
Statins modulate the stability and activity of Rho GTPases 
by acting on their sub-cellular localization and inhibiting the 
synthesis of farnesyl- and geranylgeranyl pyrophosphate, 
the isoprenoids required for the prenylation of Rho proteins. 
They also alter Rho expression at transcriptional level, 
although the underlying mechanism is still unclear.
However, the inhibition of Rho (and particularly RhoA) is 
a determinant factor in stabilizing the mRNA of endothelial 
NO synthase (eNOS) and improving endothelium-dependent 
relaxation (Figure 1).
It has been demonstrated that RhoA affects vasomo-
tion by activating Rho-kinases (ROCK), which inactivates Vascular Health and Risk Management 2006:2(4) 465–475
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myosin light chain phosphatase (MLCP) and reduces the 
expression of eNOS (Somlyo 2002). Direct inhibition of 
ROCK by speciﬁ  c inhibitors such as hydroxyfasudil and 
Y27632 increases the half-life and expression of eNOS 
mRNA (Rikitake et al 2005).
Furthermore, ROCK inhibits the serin/threonine 
kinase Akt phosphorylation and activity, and thus has 
negative effects on eNOS activity. Akt can phosphorylate 
eNOS on Ser 1179, and that phosphorylation enhances 
the enzyme’s ability to generate NO (Fulton et al 1999). 
Interestingly, the membrane compartmentalization of both 
proteins (inside the Golgi region and plasma membrane 
of endothelial cells) is required for Akt’s functional in-
teraction with eNOS. It is not fully understood how the 
phosphorylation of eNOS enhances NO release, but it 
seems to be mediated by the introduction of a negative 
charge that ‘opens’ the structure and thus permits acti-
vated calmodulin binding at lower calcium concentrations 
(Salerno et al 1997). In vitro data suggest that enzyme 
activity is enhanced in a Ca2+-independent manner, but is 
due to greater Ca2+-sensitization (Dimmeler et al 1999).
The bioavailability of NO may also be inﬂ  uenced by 
RhoA in a ROCK-independent manner. Non-ﬁ  lamentous 
actin (G-actin) interacts with eNOS mRNA, and changes 
in actin polymerization affect eNOS mRNA stability and 
down-regulate eNOS expression (Searles et al 2004). Recent 
studies have demonstrated that cytoplasmatic ﬁ  laments and 
microtubules are necessary to transport mRNA within the 
cytoplasm and anchor them at speciﬁ  c sub-cellular locations 
(Bassell and Singer 1997; Nasmyth and Jansen 1997). The 
cytoskeleton anchoring of mRNAs, and their co-localisation 
with ribosomes and RNA-binding protein complexes are 
necessary for their translational expression and stability. The 
Rho-controlled reorganisation of the actin cytoskeletron may 
therefore play a key role in the movement and compartmen-
talisation of speciﬁ  c mRNAs.
Endothelial dysfunction and vasoactive 
agonists
The partial reversion of endothelial dysfunction induced by 
statin treatment is not totally due to improved NO bioavail-
ability, but also to the better regulated expression of vaso-
active factors. The regulation of vascular tone is a complex 
process that involves the concerted action of many factors; 
in particular, endothelin-1 (ET-1) and angiotensin II (Ang II) 
elicit contractile and proliferative activities in the vascular 
smooth muscle layer. An imbalance between Ang II and NO 
is often caused by a loss of NO due to endothelial dysfunction 
and oxidative stress and/or the enhancement of Ang II local 
tissue activity (Dzau 2001).
Ang II, which is the primary effector of the renin-angio-
tensin system (RAS), is a multifunctional hormone that plays 
important autocrine and paracrine roles in vascular function 
(Campbell and Habener 1986). Albeit indirectly, Ang II 
and NO interact with each other in the vasculature to inﬂ  u-
ence vascular tone, cell growth, apoptosis and inﬂ  ammation 
(Fig. 2). Via AT1 receptor-coupled G protein, Ang II activates 
phospholipase C (PLC) which in turn produces inositol 
1,4,5-triphosphate (IP3), and stimulates Ca2+ mobilisation. 
The Ca2+-mediated activation of myosin light-chain kinase 
(MLCK) leads to the phosphorylation of MLCK and smooth 
muscle contraction. Ang II also induces Ca2+ sensitization 
of the contractile apparatus by activating RhoA/Rho kinase, 
which in turn inactivates myosin light-chain phosphatases 
(MLCP). A recent in vivo study has shown that Ang II infu-
sion decreases NO production and uncouples eNOS in rat 
aortas, thus causing superoxide rather than NO production 
(Mollnau et al 2002). Interestingly, the long-term infusion 
of Ang II causes endothelial dysfunction associated with 
decreases in guanylyl cyclase (GC) expression and cGMP-
dependent protein kinase (PKG) activity in rat aorta (Mollnau 
et al 2002).
On the contrary, by activating soluble guanylyl cyclase 
(sGC), NO stimulates PKG and reduces Ca2+ levels by down-
regulating IP3 production and decreasing Ca2+ mobilization. 
PKG inactivates the RhoA/Rho kinase signaling pathway 
to inhibit RhoA-induced Ca2+ sensitization. The results of a 
number of experimental studies suggest that NO may directly 
inhibit ACE activity reducing plasma Ang II concentrations 
Figure 1 Statins inhibit the activation of Rho signaling, which negatively inﬂ  uences 
eNOS mRNA stability and activity, leading to an increased NO bioavailability.Vascular Health and Risk Management 2006:2(4) 465–475
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and decrease AT1 receptor mRNA expression at transcrip-
tional level (Kumar and Das 1997; Ackermann et al 1998; 
Wu et al 2000).
Recent studies have demonstrated that statins may pre-
vent harmful Ang II-induced events, such as the production 
of reactive oxygen species in vascular smooth muscle cells 
(VSMCs), cardiac hypertrophy and end-organ damage 
(Wassmann et al 2001; Park et al 2000). In particular, it 
has been found in an in vivo model of arterial neointimal 
thickening that ﬂ  uvastatin inhibits Ang II-mediated ERK 
phosphorylation, and the tyrosine- and serine-induced 
phosphorylations of STAT1 and STAT3 that are known 
to be activated by many extracellular signaling proteins, 
including cytokines, growth factors, and Ang II via the 
AT1 receptor. Furthermore, in vitro and in vivo studies 
have shown that the effects of statins on AT1 receptor-
mediated actions affecting VSMCs may also be mediated 
by decreasing AT1 receptor expression (Ichiki et al 2001; 
Wassmann et al 2001). Various ﬁ  ndings indicate that pa-
tients with high levels of LDL-cholesterol may also increase 
vascular responses to Ang II, and it is known that hyper-
cholesterolemia is closely associated with AT1 receptor 
upregulation (Nickenig et al 1997, 1999). Statin treatment 
improves vascular responsiveness to Ang II (although not in 
a dose-dependent manner), and seems to be closely related 
to serum cholesterol levels.
In vascular endothelial cells, statins also affect the 
expression of pre-pro-endothelin-1, a precursor of endo-
thelin-1 (ET-1), which elicits potent contractile and prolif-
erative action in VSMCs (Hirata 1996). Statins-mediated 
inhibition of the activity of Rho proteins downregulates 
pre-pro-endothelin-1 gene expression, an effect that is 
independent of their action on NO.
Statins and caveolae
The endothelial cell plasma membrane consists of liquid-
ordered microdomains (lipid rafts), that are assembled from 
lipid constituents and have distinct biophysical characteristics 
and limited random movement (Brown and London 2000; 
Simons and Ehehalt 2002). These regions are involved 
in the local sequestration of proteins that mediate signal 
transduction in a variety of cell types, including endothelial 
and vascular smooth muscle cells. In certain pathological 
situations, such as hyperlipidemia, the composition of some 
membrane microdomains are altered and thus contribute to 
the mechanisms of atherogenesis in vascular cells.
Caveolae are the most widely studied lipid rafts. Their 
principal component is the protein caveolin, a scaffolding 
element that efﬁ  ciently binds cholesterol and interacts with 
various signalling macromolecules, including G proteins 
(Smart et al 1999; Gargalovic and Dory 2003). Caveolin 
also inhibits eNOS by blocking its access to cofactors, and 
regulates the production of NO in the endothelium (Ju et al 
1997; Feron et al 1998).
The high caveolae levels under condition of hypercholes-
terolemia are associated with reduced endothelial NO synthe-
sis and increased superoxide levels, SMC proliferation and 
leukocyte adhesion (Vergnani et al 2000). The therapeutic 
beneﬁ  t of statins is mainly due to their restoration of normal 
endothelial NO levels by means of various mechanisms, 
including the upregulation of eNOS expression (Laufs et al 
1998). They also stimulate endothelial NO production by 
greatly decreasing plasma membrane caveolin levels: a recent 
study on endothelial cells (ECs) found that atorvastatin re-
duced the abundance of caveolin-1 in the absence or presence 
of LDL-cholesterol, and promoted NO production regardless 
of the level of extracellular LDL-cholesterol (Feron et al 
2001). These results highlight the central role of inhibiting the 
mevalonate pathway in peripheral cells by reducing the syn-
thesis of isoprenoid intermediates regardless of cholesterol 
synthesis. Moreover, the beneﬁ  cial effect of atorvastatin on 
eNOS activity was greater in the cells expressing high levels 
of caveolin. Finally, the statin promoted the agonist-induced 
association of eNOS and chaperone Hsp90, thus leading to 
increased activity (Feron et al 2001).
In addition to modulating the physical and chemical 
properties of membrane lipids, hypercholesterolemia has 
also been associated with the disruption of active L-arginine 
transport, which affects the capacity of endothelial cells to 
Figure 2 Ang II and NO functions interplay to inﬂ  uence vascular tone, through 
different effects on RhoA pathway.Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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generate NO: ie, L-arginine deﬁ  cit leads eNOS to overpro-
duce superoxide from oxygen instead of NO. By improving 
L-arginine uptake through amino acid transport, statins may 
also enhance NO production and interfere with superoxide 
formation.
Effects of statins on endothelial 
dysfunction
Many studies have demonstrated the beneﬁ  cial clinical 
effects of statins on endothelial dysfunction, but the under-
lying mechanisms remain largely unknown. Nevertheless, 
all researchers believe that, in addition to the reduction in 
cholesterol, a NO-dependent process is also involved. In vitro 
and in vivo studies have conﬁ  rmed that statins enhance the 
expression of eNOS by means of post-transcriptional/transla-
tional mechanisms (Laufs et al 1998, 2000). In particular, the 
use of different animal models has been useful in improving 
our understanding of the role of individual risk factors, such 
as hypertension, hypertriglyceridemia, hyperinsulinemia, 
hyperglycemia and insulin resistance in endothelial dysfunc-
tion, and correlating the improvement in endothelial function 
due to statins treatment with changes in these factors.
Animal studies
Chronic treatment with simvastatin improves endothelium-
dependent acetylcholine relaxations of aorta from hyperten-
sive rats (SHR) by means of a mechanism that is independent 
of the cyclo-oxygenase pathway (de Sotomayor et al 1999). 
The improved endothelial function in the treated animals can 
be attributed to the normalization of deranged NOS activity, 
partly mediated by the promotion of superoxide dismutase 
(SOD) (Carneado et al 2002).
The same authors have also shown that simvastatin 
improves endothelium-dependent acetylcholine relaxations 
in vessels from aged Wistar rats. The mechanisms involved 
enhanced endothelial NO vasodilatation due to increased 
eNOS expression, decreased participation of TXA2 associ-
ated with the decreased expression of the COX-2 isoform, 
and enhanced vessel antioxidant properties (de Sotomayor 
et al 2005).
Statins improve endothelial health in many situations, 
but have failed in the well-known model of cardiovascular 
disease offered by DOCA-salt rats that develop hypertension, 
cardiovascular hypertrophy, inﬂ  ammation and endothelial 
dysfunction. At a dose that decreased plasma cholesterol 
levels, rosuvastatin attenuated aortic media thickness and 
vascular hypertrophy, but did not affect the developing 
hypertension. It surprisingly increased aortic responses to 
acetylcholine in male Wistar rats, but had no effect on the 
reduced responses to noradrenaline, sodium nitroprusside 
and acetylcholine of DOCA-salt rats. These results may be 
attributed to species-related differences and variations in the 
capacity of statins to penetrate vascular cell membranes, but 
it is also conceivable that lowering blood pressure is neces-
sary to improve endothelial dysfunction in DOCA-salt rats 
(Loch et al 2006).
A recent study investigated in vivo a possible molecu-
lar mechanism of vascular dysfunction and the effects of 
ﬂ  uvastatin in obese Zucker rats, a model of diabetes mellitus 
(Nishimatsu et al 2005). Fluvastatin partially (but signicantly) 
reduced Ang II-induced vasoconstriction and improved 
endothelium-dependent vasorelaxation via the phosphati-
dylinositol 3-kinase/protein kinase Akt (PI3K/Akt)-depen-
dent and NO/cGMP-dependent pathways in rat aorta. This 
had previously been observed in an in vitro study of endothe-
lial cells in which statins seemed to stimulate the membrane 
translocation of Akt and its activating phosphorylation by 
PI3-kinase (Skaletz-Rorowski et al 2003): statin stimulation 
promoted the association of tyrosine phosphorylated protein 
with the p85 subunit of PI3-kinase, and Akt translocation 
was inhibited by mevalonate and wortmannin, a PI3-kinase 
inhibitor, thus leading to the inactivation of the enzyme. It 
has been reported that the Akt-dependent phosphorylation 
of eNOS is necessary for the full activation of eNOS and 
endothelium-dependent vasorelaxation, and so impaired 
PI3K/Akt activation may have been involved in the reduced 
endothelium-dependent vasorelaxation (Dimmeler et al 1999; 
Fulton et al 1999).
Furthermore, Akt signaling is subject to regulation by a 
rapidly exchanging pool of cholesterol within cells. Some 
authors suggest that this endothelial cholesterol pool is more 
sensitive to the statin-mediated inhibition of endogenous 
cholesterol synthesis than it is to changes in exogenous 
cholesterol delivery from the serum by LDLs. In this regard, 
it may be relevant that PI3-kinase activity in ﬁ  broblasts is 
negatively regulated by the recruitment of caveolin-1, an 
intracellular cholesterol transport protein, to PI3-kinase-
associated receptor complexes within lipids rafts (Zundel 
et al 2000). It has also been shown that the statin-induced 
inhibition of cholesterol synthesis in endothelial cells can im-
prove the inhibitory action of caveolin-1 on eNOS (Feron et 
al 2001), the activity of which is controlled by Akt-mediated 
phosphorylation (Fulton et al 1999; Dimmeler et al 1999).
Cerivastatin treatment improves endothelial dysfunction 
in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a 
useful model of obese type 2 diabetes. The restoration of Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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endothelial function was related to an increased in the aortic 
expression of CD36, a gene encoding a fatty acid transporter, 
and PPAR-γ. This study is an interesting example of an inter-
relationship between cholesterol and fatty acid metabolism 
which may lead to marked beneﬁ  cial effects on endothelial 
function in patients with diabetic hyperlipidemia and insulin-
resistance syndromes (Nakamura et al 2004).
Human studies
Strong evidence that lowering LDL alone is not enough to 
improve endothelial dysfunction has been provided by the 
inability of ezetimibe, in comparison with atorvastatin alone 
or in combination with ezetimibe, to improve endothelial va-
sodilator function in the forearm circulation of patients with 
coronary artery disease (CAD), despite its LDL-cholesterol 
lowering effect (Fichtlscherer et al 2006). These ﬁ  ndings 
suggest that the lipid-lowering capacity of atorvastatin is not 
the primary mechanism underlying the beneﬁ  cial effects of 
short-term atorvastatin therapy in patients with CAD.
In subjects with moderately high total serum cholesterol 
levels, the vasodilatator response to acetylcholine and base-
line blood ﬂ  ow signiﬁ  cantly increased after four weeks’ 
treatment with simvastatin, which simultaneously increased 
the vasoconstrictor response to L-NMMA, whereas the 
response to the endothelium-independent vasodilator sodium 
nitroprusside remained unchanged. None of these effects 
were related to the decrease in cholesterol levels (O’Driscoll 
et al 1997). Statin therapy also improves endothelial function 
in normocholesteremic patients with chronic heart failure 
(CHF) and, if the treatment is long, stabilizes neurohor-
monal imbalances and provides measurable clinical beneﬁ  ts. 
Furthermore, these beneﬁ  cial effects on the endothelium are 
dose dependent (van der Harst et al 2005).
Some new aspects have been highlighted by a recent study 
of atorvastatin in hyperlipidemic patients. The improvement 
in endothelial function preferentially occurred in patients 
with pre-existing endothelial dysfunction and completely 
disappeared within the 36 hours following the withdrawal 
of the statin (Taneva et al 2006). This last observation cor-
responds to results from cell cultures and animal experiments 
in which the lowering of eNOS and/or NO levels occurred 
after the discontinuation of statins (Laufs et al 2000; Gertz 
et al 2003; Xing et al 2005). One possible molecular mecha-
nism of this may be related to the increase in membrane Rho 
expression after statin withdrawal that has been found both 
in vitro and in vivo (Laufs et al 2000).
However, as the findings conflict with the results 
obtained in non-diabetic subjects, it is intriguing to note 
that statins do not seem to improve endothelial function 
consistently in patients with type 2 diabetes. Only a few 
published clinical studies have assessed the effect of statins 
on the microcirculation in subjects with type 2 diabetes, and 
their results were varied. Some found that statin therapy 
failed to improve endothelial dysfunction, and the authors 
suggested that lowering LDL alone may not be sufﬁ  cient 
to improve endothelial function in the absence of glycemic 
control (Mansourati et al 2001; van Etten et al 2002; van 
Venrooij et al 2002; Fegan et al 2005). Another recently 
suggested explanation for the failure of statins to improve 
endothelial function in such cases is the diabetes-speciﬁ  c ac-
cumulation of advanced glycosylation end-product (AGE) 
products (Sowers 2002) that leads to vascular thickening, 
loss of elasticity, and the cross-linking of subendothelial 
structural proteins.
However, two studies have demonstrated improved 
endothelial function with statins in diabetes and, although 
CRP levels did not decrease signiﬁ  cantly, the change corre-
lated with the change in endothelium-dependent vasodilata-
tion (Tsunekawa et al 2001; Tan et al 2002).
Anti-inﬂ  ammatory properties 
of statins
Inﬂ  ammation plays a pivotal role in all stages of atheroscle-
rosis, from the nascent lesion to acute coronary syndromes 
(Libby et al 2002).
A number of in vitro studies have described the ben-
eﬁ  cial effects of statins in decreasing the levels of CD 11b 
adhesion molecules (Weber et al 1997), leukocyte function 
antigen-1 (LFA-1) (Weitz-Schmidt et al 2001), and ICAM-
1 and VCAM-1 (Bernot et al 2003; Zapolska-Downar 
et al 2004; Landsberger et al 2006), and other studies have 
shown that they reduce the secretion of pro-inﬂ  ammatory 
cytokines (such as interleukin IL-6, IL-1β and TNF-α) and 
chemokines, such as IL-8 and MCP-1 (Romano et al 2000; 
Wang et al 2005). Interestingly, statins inhibit the produc-
tion of TNF-α in endothelial cells as well as the CRP-stimu-
lated activation of NF-kB, a strong biomarker of systemic 
inﬂ  ammation in cardiovascular diseases. It has been shown 
that CPR induces plasminogen activator inhibitor (PAI-1) 
expression and complement activation, and decreases eNOS 
expression, thus leading to a propensity for thrombosis, 
inﬂ  ammation and endothelial dysfunction. Recent clinical 
studies have found that various statins reduce CRP levels, 
and that this is at least partially independent of their lipid-
lowering properties (Ridker 2003; Nawawi et al 2003; 
Sugiyama et al 2005).Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Numerous in vitro and in vivo experiments have shown 
that the anti-inﬂ  ammatory effects of statins are partially medi-
ated by vascular endothelial NO (Scalia et al 2001; Stalker 
et al 2001). This cholesterol-independent effect of statins is 
absent in eNOS-deﬁ  cent mice, thus suggesting that eNOS 
mediates the protective vascular effects of statins (Stalker 
et al 2001).
NO mediates the beneﬁ  cial effects 
of statins on vascular health
Recent studies have shown that endothelial dysfunction plays 
an important role as an independent risk factor (Widlansky 
et al 2003) and, together with inﬂ  ammation, triggers cardio-
vascular diseases (Drexler et al 1992; Tousoulis et al 2005). 
Furthermore, it has been recognized that endothelium-derived 
NO is an anti-inﬂ  ammatory and anti-arteriosclerotic molecule 
as it protects nuclear transcription factor (NF-kB) from 
activation by oxidized LDL or cytokines, and thus prevents 
or attenuates the transcription and expression of adhesion 
molecules (Marui et al 1993). It has also been shown that 
the inhibition of NO synthesis in cultured endothelial cells 
increases the expression of the gene coding for MCP-1, and 
that MCP-1 expression is associated with the activation 
of NF-kB (Zeiher et al 1995). Therapies that increase NO 
bioactivity may reduce the synthesis of pro-inﬂ  ammatory 
proteins on the endothelial cell surface, which may reduce 
inﬂ  ammation.
The capacity of statins to improve endothelial dysfunc-
tion and reduce inﬂ  ammation has been demonstrated in 
numerous experimental studies. Long-term treatment with 
simvastatin normalizes acetylcholine-induced relaxation 
in rats treated with L-NAME without affecting response 
to the nitrovasodilator itself (Perez-Guerrero et al 2003). 
The inhibition of NO synthesis by N-nitro-arginine methyl 
ester induces early inﬂ  ammation characterized by increased 
monocyte inﬁ  ltration coronary vessels and increased MCP-1 
expression (Takemoto et al 1997; Tomita et al 1998). In the 
same animal model, pravastatin and cerivastatin inhibited 
vascular inﬂ  ammation by increasing eNOS expression and 
restoring NO-generating capacity by inhibiting Rho activity 
(Ni et al 2001). A recent study has suggested a novel molecu-
lar mechanism by which statins regulate vascular inﬂ  amma-
tion by ﬁ  nding that simvastatin increased NO production in 
human aortic endothelial cells (HAECs), and this covalently 
modiﬁ  ed N-ethylmaleimide sensitive factor (NSF), a key 
regulator of endothelial exocytosis. The nitrosylation of NSF 
blocked the externalization of P-selectin to the endothelial 
surface, which otherwise activates leukocyte rolling, the ﬁ  rst 
step in leukocyte inﬂ  ammation (Yamakuchi et al 2005). The 
statin also modiﬁ  ed the second step in leukocyte trafﬁ  cking 
by blocking the interaction of LFA-1 with intercellular adhe-
sion molecule-1 (VCAM-1) but, interestingly, not in eNOS 
knockout mice.
In patients with heart failure, atorvastatin treatment 
signiﬁ  cantly improves forearm vasodilatory response to 
reactive hyperemia and reduced serum levels of IL-6, TNF-α 
and soluble VCAM-1, but has no effects on MCP-1 (Tou-
soulis et al 2005). Statins also improve arterial stiffness and 
decrease the plasma levels of hsCRP, a sensitive marker of 
the chronic inﬂ  ammation of arteriosclerotic lesions in patients 
with hypercholesterolemia (Matsuo et al 2005).
In hypercholesterolemic patients with angiographically-
documented coronary artery disease, simvastatin signiﬁ  cantly 
improved the percent ﬂ  ow-mediated dilator response to 
hyperemia, whereas the response to nitroglycerin was not 
signiﬁ  cantly modiﬁ  ed (Koh et al 2003). In the same patients, 
it signiﬁ  cantly lowered the plasma levels of TNF-α, CRP, 
ﬁ  brinogen and ICAM-1, but had no effect on E-selectin and 
VCAM-1; furthermore, the greatest reduction in plasma 
TNF-α and CRP levels occurred in the patients with the 
highest baseline levels. It is interesting to note that there 
was a signiﬁ  cant inverse correlation between the percent-
age of ﬂ  ow-mediated dilatation and plasma TNF-α levels, 
and a positive correlation between the latter and changes in 
plasma nitrate levels.
High-dose atorvastatin acutely increased endothelium-
dependent forearm blood flow (FBF) in subjects with 
normal vascular function, and rapidly decreased the levels 
of the inflammation marker hs-CPR (Laufs et al 2001). 
Furthermore, its withdrawal has been found to induce a 
rapid deterioration in endothelial function, a rebound-like 
decrease in NO bioavailability, and increased inflamma-
tion in clinical and experimental studies (Thomas and 
Mann 1998; Laufs and Liao 2000; Laufs et al 2000). These 
data are in line with the recent finding that the discontinu-
ation of statin treatment induces vascular complications 
in patients with acute coronary syndromes (Heeschen 
et al 2002; Li et al 2006).
Statin modulates thrombosis 
and coagulation
Nitric oxide is the major mediator synthesized by the 
endothelium. It regulates vascular homeostasis and blood 
flow, and a decrease in its bioavailability is related to 
vasoconstriction, vascular smooth muscle proliferation, 
platelet aggregation and endothelial-leukocyte adhesion Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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The (ATROCAP) study provides deﬁ  nite in vivo evidence 
that statins affect TF expression and activity, and macrophage 
inﬁ  ltration in human vessels (Cortellaro et al 2002). These 
data strongly indicate that statins attenuate atherosclerotic 
plaque thrombogenicity by reducing cell-mediated throm-
bin generation. Studies of the effects of statins on plasma 
ﬁ  brinogen and factor VII levels have led to very contrasting 
results (Colli et al 2004).
Additional features of endothelial cell dysfunction in-
clude atheroma ﬁ  brinolytic imbalance. In advanced lesions, 
a state of hypoﬁ  brinolysis prevails because of the high levels 
of plasminogen activator inhibitor-1 (PAI-1) released by acti-
vated cells within the atheroma and the platelets incorporated 
in mural thrombi (Robbie et al 1996). Although, in vitro and 
ex vitro studies have shown that different statins induce tis-
sue-type plasminogen activators (t-PA) and reduce PAI-1, 
the results of in vivo studies are conﬂ  icting (Colli et al 2004). 
These results may be explained by differences in metabolic 
proﬁ  les and genetic backgrounds, which are known to have 
a considerable effect on PAI-1 levels.
Conclusion
Many of the beneﬁ  cial pleiotropic effects of statins occur 
as a result of modulated endothelial function and reduced 
inﬂ  ammatory processes. Attempting to understand these 
properties of statins is an exciting ﬁ  eld of research that will 
also improve our understanding of vascular biology in health 
and disease, and thus enable the better use of this drug class 
in clinical practice.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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